Article Text

other Versions

PDF

Correspondence
Safety of long-acting β-agonists in asthma
  1. Gustavo J Rodrigo1,
  2. Jose A Castro-Rodriguez2
  1. 1Emergency Department, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay
  2. 2School of Medicine, Pontificia Universidad Catolica de Chile, Las Condes, Santiago, Chile
  1. Correspondence to Dr Gustavo J Rodrigo, Emergency Department, Hospital Central de las Fuerzas Armadas, Uruguay, Av. 8 de Octubre 3020, Montevideo 11300, Uruguay; gurodrig{at}adinet.com.uy

Statistics from Altmetric.com

The study by Wolfe et al1 certainly does not support our claim that serious asthma exacerbations are more frequent in patients receiving formoterol 24 μg twice daily than in those receiving 12 μg twice daily, or placebo.2 Actually, this statement should have been based on the review by Mann et al,3 that assessed data from three prospective, randomised, placebo-controlled and double-blind studies of formoterol at different dosages submitted to the US Food and Drug Administration. The authors concluded that more patients treated regularly with formoterol 24 μg twice daily had serious asthma exacerbations than did patients who had been treated with formoterol 12 μg twice daily, or placebo (4.5% vs 2.0%, vs 0.4%, respectively). In any case, evidence from controlled studies suggests that the use of long-acting β-agonists added to inhaled corticosteroids is safe and effective for the treatment of asthma.

References

View Abstract

Footnotes

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.